Mrs Lucia Yuma Martin, PA-C in Annandale, NJ - Physician Assistant

Mrs Lucia Yuma Martin, PA-C is a Physician Assistant based in Annandale, New Jersey. Mrs Lucia Yuma Martin is licensed to practice in New Jersey (license number 25MP00168400) and her current practice location is 1465 State Route 31 S, Annandale, New Jersey. She can be reached at her office (for appointments etc.) via phone at (908) 735-5100.

NPI number for Mrs Lucia Yuma Martin is 1902947351 and her current mailing address is Po Box 60, Lansdale, Pennsylvania. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1902947351.

Contact Information

	Mrs Lucia Yuma Martin, PA-C
	1465 State Route 31 S, Annandale, NJ 08801-3129
	(908) 735-5100
	(908) 735-0004

Provider's Profile

Full Name	Mrs Lucia Yuma Martin
Gender	Female
Speciality	Physician Assistant
Location	1465 State Route 31 S, Annandale, New Jersey
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1902947351
Provider Enumeration Date: 02/09/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Mrs Lucia Yuma Martin such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1902947351	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
363A00000X	Physician Assistant	25MP00168400 (New Jersey)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mrs Lucia Yuma Martin is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mrs Lucia Yuma Martin, PA-C Po Box 60, Lansdale, PA 19446-0060 Ph: (610) 847-8450	Mrs Lucia Yuma Martin, PA-C 1465 State Route 31 S, Annandale, NJ 08801-3129 Ph: (908) 735-5100

News Archive

UC San Diego researchers receive NIH grant to develop scaffolds

University of California, San Diego NanoEngineers won a grant from the National Institutes of Health (NIH) to develop the tools to manufacture biodegradable frames around which heart tissues functional blood vessels included will grow.

FDA approves combination immunotherapy for treatment of kidney cancer

The standard of care for kidney cancer patients continues to improve. The U.S. Food and Drug Administration granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer.

Orexigen's Contrave COR-I trial results published online in journal Lancet

Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.

Alarming link between marijuana and increased heart risk

Marijuana use is rising steadily across the US as more and more states enact laws making it a legal recreational and medicinal agent. However, a new study underlines the fact that this is, in fact, playing with an unknown substance, which may cause serious bodily harm. The review article, published in the Journal of the American College of Cardiology, shows that more than 2 million adults who currently have heart or vascular disease gave a history of being currently on marijuana products, or having used them in the past.

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

Mrs Lucia Yuma Martin, PA-C - Physician Assistant in Annandale, NJ